Características clínicas y anticuerpos antifosfolipídicos (anticardiolipina-β2GP-1) en líquido cefalorraquídeo y suero en una muestra de pacientes con esclerosis múltiple en México

Carrillo‐Mora, Paul; González-Villalva, Adriana

doi:10.1016/s0213-4853(10)70029-3

Neurología

2010

DOI: 10.1016/s0213-4853(10)70029-3

|View full text |Cite

Características clínicas y anticuerpos antifosfolipídicos (anticardiolipina-β2GP-1) en líquido cefalorraquídeo y suero en una muestra de pacientes con esclerosis múltiple en México

Paul Carrillo‐Mora

Adriana González-Villalva

Abstract: The clinical-demographic characteristics in patients studied in this work were similar to those previously reported, and the levels of anti-cardiolipin-beta2GP-1 were negative, thus indicating the existence of different clinical and demographic variables influencing their detection.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2013

2022

Publication Types

Select...

Article5

Relationship

Self Cite0

Independent5

Authors

Journals

Cited by 6 publications

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Serum anticardiolipin antibodies in patients with neuromyelitis optica spectrum disorder

Long

Zheng

et al. 2013

J Neurol

View full text Add to dashboard Cite

The presence of anticardiolipin antibodies (ACLA) in multiple sclerosis (MS) patients has been reported, but there are some debates on the relationship between ACLA and MS. We assessed the clinical features of neuromyelitis optica spectrum disorders (NMOSD) patients with ACLA. A consecutive cohort of 480 subjects with NMOSD (n = 70), MS (n = 90) and control (n = 220) were analysed retrospectively. Patients' serum was tested by a dot-immunogold filtration assay for the presence of ACLA-IgG, IgM and IgA antibodies. In MS patients, 5 (5.6 %) of the 90 patients showed ACLA-IgG reactivity in the serum. In NMOSD patients, 32 (45.7 %) of the 70 patients showed ACLA reactivity in the serum, among which ACLA-IgG seropositivity was 45.7 % (32/70), ACLA-IgG + IgM seropositivity was 8.6 % (6/70), and ACLA-IgG + IgA seropositivity was 4.3 % (3/70). NMOSD patients were higher in ACLA-IgG (p < 0.0001) and ACLA-IgG + IgM (p = 0.006) than the MS patients. NMOSD patients had higher ACLA-IgG than the control patients (p < 0.0001). In comparison with the controls, the MS patients were lower in ACLA for IgG (p = 0.014) and IgM (p = 0.004). Seropositive ACLA patients increased in age (p = 0.013) and had higher D-dimer levels (DD) (p = 0.002) than the seronegative NMOSD patients. Furthermore, positive ACLA-IgG + IgM patients were increased in age (p = 0.001), had higher baseline EDSS (p = 0.001), antithrombin III activity (p = 0.04), and DD levels (p = 0.005) than the pure positive ACLA-IgG NMOSD patients. Patients with NMOSD had more occurrences of ACLA than patients with MS. NMOSD patients with positive ACLA-IgG + IgM had a worse outcome that may be associated with elder age and abnormal coagulation parameters in blood.

show abstract

Serum anticardiolipin antibodies in patients with neuromyelitis optica spectrum disorder

Long

Zheng

et al. 2013

J Neurol

View full text Add to dashboard Cite

show abstract

Prevalence and clinical features of multiple sclerosis in Latin America

Ojeda

Díaz-Cortes

Rosales

et al. 2013

Clinical Neurology and Neurosurgery

View full text Add to dashboard Cite

Relevance of antiphospholipid antibodies in multiple sclerosis: A systematic review and meta analysis

Merashli

Alves

Gentile

2017

Seminars in Arthritis and Rheumatism

View full text Add to dashboard Cite

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

hi@scite.ai

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Características clínicas y anticuerpos antifosfolipídicos (anticardiolipina-β2GP-1) en líquido cefalorraquídeo y suero en una muestra de pacientes con esclerosis múltiple en México

Abstract: The clinical-demographic characteristics in patients studied in this work were similar to those previously reported, and the levels of anti-cardiolipin-beta2GP-1 were negative, thus indicating the existence of different clinical and demographic variables influencing their detection.

Cited by 6 publications

References 41 publications

Serum anticardiolipin antibodies in patients with neuromyelitis optica spectrum disorder

Serum anticardiolipin antibodies in patients with neuromyelitis optica spectrum disorder

Prevalence and clinical features of multiple sclerosis in Latin America

Relevance of antiphospholipid antibodies in multiple sclerosis: A systematic review and meta analysis

Contact Info

Product

Resources

About